Breast Cancer Now media statements
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England's proposed new standards
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new data from major trial OlympiA shows adjuvant olaparib improved survival in patients
On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society for Medical ...
We respond to research about artificial sweeteners and breast cancer risk
Commenting on research published in PLOS Medicine about artificial sweeteners and breast cancer risk, Dr Kotryna Temcinaite, Senior Research...
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new research into how salt in tumours could help diagnose and treat breast cancer
New research, funded by Breast Cancer Now and Cancer Research UK at the universities of York and Cambridge, has shown that analysing sodium ...
We support latest Emmerdale storyline on Faith Dingle's Secondary Breast Cancer diagnosis
Catherine Priestley, Clinical Nurse Specialist at Breast Cancer Now, said:
We comment on saliva samples used to determine breast cancer risk in women of screening age
We have commented on new research published in Genetics in Medicine titled 'Breast cancer risk stratification in women of screening age: Inc...
We welcome NICE approval of pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We comment on new research which shows the drug trastuzumab deruxtecan may benefit even more breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to new findings from the Lumina trial which suggest some patients could avoid radiotherapy
Breast Cancer Now has commented on findings from the Lumina trial presented at the American Society of Clinical Oncology (ASCO).